Should I buy or sell AVITA Medical stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AVITA Medical in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RCEL shares. View RCEL analyst ratings or view top-rated stocks .

What is AVITA Medical's stock price target for 2024?

5 analysts have issued twelve-month price targets for AVITA Medical's stock. Their RCEL share price targets range from $21.00 to $40.00. On average, they expect the company's share price to reach $27.80 in the next twelve months. This suggests a possible upside of 196.4% from the stock's current price. View analysts price targets for RCEL or view top-rated stocks among Wall Street analysts .

How have RCEL shares performed in 2024?

AVITA Medical's stock was trading at $13.72 at the start of the year. Since then, RCEL shares have decreased by 31.6% and is now trading at $9.38. View the best growth stocks for 2024 here .

Are investors shorting AVITA Medical?

AVITA Medical saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 726,200 shares, an increase of 22.9% from the March 15th total of 590,700 shares. Based on an average trading volume of 165,600 shares, the days-to-cover ratio is presently 4.4 days. Currently, 3.1% of the shares of the company are sold short. View AVITA Medical's Short Interest .

When is AVITA Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our RCEL earnings forecast .

How can I listen to AVITA Medical's earnings call?

AVITA Medical will be holding an earnings conference call on Monday, May 13th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link .

How were AVITA Medical's earnings last quarter?

AVITA Medical, Inc. (NASDAQ:RCEL) released its earnings results on Thursday, February, 22nd. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.34) by $0.06. The firm earned $14.20 million during the quarter, compared to analysts' expectations of $14.10 million. AVITA Medical had a negative net margin of 70.56% and a negative trailing twelve-month return on equity of 54.80%.

What guidance has AVITA Medical issued on next quarter's earnings?

AVITA Medical issued an update on its first quarter 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $14.8 million-$15.6 million, compared to the consensus revenue estimate of $15.8 million.

What other stocks do shareholders of AVITA Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVITA Medical investors own include NVIDIA (NVDA) , Block (SQ) , Alibaba Group (BABA) , Micron Technology (MU) , Netflix (NFLX) , PayPal (PYPL) , Twilio (TWLO) , AbbVie (ABBV) , Inovio Pharmaceuticals (INO) and Livongo Health (LVGO) .

How do I buy shares of AVITA Medical?

Shares of RCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:RCEL

AVITA Medical (RCEL) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free RCEL Stock Alerts

$9.38

-0.32 (-3.30%)

(As of 04/17/2024 ET)

Compare

Today's Range: $9.34
▼
$9.88
50-Day Range: $9.38
▼
$18.31
52-Week Range: $9.16
▼
$21.70

Volume: 227,135 shs
Average Volume: 203,680 shs
Market Capitalization: $241.16 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $27.80

Get AVITA Medical alerts:

AVITA Medical MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 196.4% Upside
$27.80 Price Target
Short Interest: Bearish
3.06% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.15
Based on 8 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.12) to ($0.19) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.99 out of 5 stars

Medical Sector

793rd out of 913 stocks

Medical Devices Industry

6th out of 7 stocks

3.4

Analyst's Opinion

Consensus Rating
AVITA Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
AVITA Medical has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.06% of the float of AVITA Medical has been sold short.
Short Interest Ratio / Days to Cover
AVITA Medical has a short interest ratio ("days to cover") of 4.4.
Change versus previous month
Short interest in AVITA Medical has recently increased by 22.94%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
AVITA Medical does not currently pay a dividend.
Dividend Growth
AVITA Medical does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RCEL.

1.6

News and Social Media Coverage

News Sentiment
AVITA Medical has a news sentiment score of -0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for AVITA Medical this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for RCEL on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
5 people have added AVITA Medical to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AVITA Medical insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.05% of the stock of AVITA Medical is held by insiders.
Percentage Held by Institutions
Only 27.66% of the stock of AVITA Medical is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for AVITA Medical are expected to grow in the coming year, from ($1.12) to ($0.19) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AVITA Medical is -6.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AVITA Medical is -6.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AVITA Medical has a P/B Ratio of 4.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About AVITA Medical Stock (NASDAQ:RCEL)

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.

RCEL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RCEL Stock News Headlines

April 15, 2024 | globenewswire.com

AVITA Medical to Announce First Quarter 2024 Financial Results

April 13, 2024 | americanbankingnews.com

BTIG Research Downgrades AVITA Medical (NASDAQ:RCEL) to Neutral

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 11, 2024 | investing.com

Avita Medical Ltd (RCEL)

April 11, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), Disc Medicine (IRON) and Avita Medical (RCEL)

April 11, 2024 | seekingalpha.com

BTIG downgrades Avita to neutral, cites lowered guidance

April 10, 2024 | globenewswire.com

AVITA Medical Updates Expected First Quarter 2024 Revenue

March 16, 2024 | finance.yahoo.com

RCEL Oct 2024 17.500 put

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 16, 2024 | finance.yahoo.com

RCEL Apr 2024 22.500 put

March 5, 2024 | seekingalpha.com

AVITA Medical: Unconvincing Growth Amid Fierce Competition In The Burn Care Sector

February 29, 2024 | finance.yahoo.com

AVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplement

February 29, 2024 | globenewswire.com

AVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplement

February 29, 2024 | globenewswire.com

AVITA Medical to Present at TD Cowen 44th Annual Health Care Conference

February 26, 2024 | nasdaq.com

AVITA Medical (RCEL) Price Target Increased by 6.80% to 26.69

February 26, 2024 | sg.finance.yahoo.com

BRIEF-Seatrium Limited Says FY Revenue S$7.3 Bln

February 23, 2024 | markets.businessinsider.com

Avita Medical Poised for Growth: Strong Q4 Performance and Promising 2024 Outlook Reinforce Buy Rating

February 23, 2024 | finance.yahoo.com

AVITA Medical, Inc. (NASDAQ:RCEL) Q4 2023 Earnings Call Transcript

February 23, 2024 | globenewswire.com

AVITA Medical to Host Investor Webinar Briefing

February 23, 2024 | msn.com

Ardelyx Posts Q4 Loss, Joins MercadoLibre, Booking Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session

February 23, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Avita Medical on Strong Financials and Expansive Growth Strategy

February 22, 2024 | globenewswire.com

AVITA Medical Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance

February 21, 2024 | msn.com

AVITA Medical Q4 2023 Earnings Preview

February 17, 2024 | finance.yahoo.com

RCEL Mar 2024 15.000 call

February 7, 2024 | finance.yahoo.com

AVITA Medical, Inc. (NASDAQ:RCEL): Are Analysts Optimistic?

February 1, 2024 | finance.yahoo.com

AVITA Medical to Announce Fourth Quarter and Full Year 2023 Financial Results

January 12, 2024 | markets.businessinsider.com

Avita Medical Poised for Growth: Buy Rating and $40 Price Target Justified by Strategic Partnerships and Positive Financial Indicators

See More Headlines

Receive RCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVITA Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2024
Today: 4/17/2024
Next Earnings (Confirmed): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:RCEL
CUSIP: N/A
CIK: 1762303
Web: www.avitamedical.com
Phone: (833) 462-8482
Fax: N/A
Employees: 207
Year Founded: 2008

Price Target and Rating

Average Stock Price Target: $27.80
High Stock Price Target: $40.00
Low Stock Price Target: $21.00
Potential Upside/Downside: +196.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.40)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-35,380,000.00
Net Margins: -70.56%
Pretax Margin: -70.43%
Return on Equity: -54.80%
Return on Assets: -38.08%

Debt

Debt-to-Equity Ratio: 0.81
Current Ratio: 7.88
Quick Ratio: 7.46

Sales & Book Value

Annual Sales: $50.14 million
Price / Sales: 4.81
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.92 per share
Price / Book: 4.89

Miscellaneous

Outstanding Shares: 25,710,000
Free Float: 25,180,000
Market Cap: $241.16 million
Optionable: Optionable
Beta: 1.33

Social Links

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. James M. Corbett (Age 66)
CEO, President & Executive Director
Comp: $1.16M
Mr. David O'Toole (Age 65)
Chief Financial Officer
Comp: $574.64k
Ms. Donna Shiroma (Age 61)
General Counsel, Chief Compliance Officer & Secretary
Comp: $688.6k
Mr. David Fencil
Senior Vice President of Global Operations
Dr. Katie Bush Ph.D.
Senior Vice President of Scientific & Medical Affairs
Ms. Jessica Ekeberg
Investor Relations Executive
Ms. Debbie Garner
Senior Vice President of Global Marketing & Strategy
Mr. Rob Hall
Senior Vice President of Human Resources
Mr. Terry Bromley
Senior Vice President of Global Sales
Dr. Niraj Doshi J.D.
P.M.P., Ph.D., Senior Vice President of Product Development & Program Management

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RCEL Stock Analysis - Frequently Asked Questions

Should I buy or sell AVITA Medical stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AVITA Medical in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RCEL shares.
View RCEL analyst ratings or view top-rated stocks.
What is AVITA Medical's stock price target for 2024?: 5 analysts have issued twelve-month price targets for AVITA Medical's stock. Their RCEL share price targets range from $21.00 to $40.00. On average, they expect the company's share price to reach $27.80 in the next twelve months. This suggests a possible upside of 196.4% from the stock's current price.
View analysts price targets for RCEL or view top-rated stocks among Wall Street analysts.
How have RCEL shares performed in 2024?: AVITA Medical's stock was trading at $13.72 at the start of the year. Since then, RCEL shares have decreased by 31.6% and is now trading at $9.38.
View the best growth stocks for 2024 here.
Are investors shorting AVITA Medical?: AVITA Medical saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 726,200 shares, an increase of 22.9% from the March 15th total of 590,700 shares. Based on an average trading volume of 165,600 shares, the days-to-cover ratio is presently 4.4 days. Currently, 3.1% of the shares of the company are sold short.
View AVITA Medical's Short Interest.
When is AVITA Medical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our RCEL earnings forecast.
How can I listen to AVITA Medical's earnings call?: AVITA Medical will be holding an earnings conference call on Monday, May 13th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were AVITA Medical's earnings last quarter?: AVITA Medical, Inc. (NASDAQ:RCEL) released its earnings results on Thursday, February, 22nd. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.34) by $0.06. The firm earned $14.20 million during the quarter, compared to analysts' expectations of $14.10 million. AVITA Medical had a negative net margin of 70.56% and a negative trailing twelve-month return on equity of 54.80%.
What guidance has AVITA Medical issued on next quarter's earnings?: AVITA Medical issued an update on its first quarter 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $14.8 million-$15.6 million, compared to the consensus revenue estimate of $15.8 million.
What other stocks do shareholders of AVITA Medical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AVITA Medical investors own include NVIDIA (NVDA), Block (SQ), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), PayPal (PYPL), Twilio (TWLO), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Livongo Health (LVGO).
How do I buy shares of AVITA Medical?: Shares of RCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RCEL) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

AVITA Medical (RCEL) Stock Price, News & Analysis

AVITA Medical MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About AVITA Medical Stock (NASDAQ:RCEL)

RCEL Stock Price History

RCEL Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

RCEL Stock Analysis - Frequently Asked Questions

Overall MarketRank^™